Results 61 to 70 of about 26,025 (223)

Differentiation Syndrome and Sweet Syndrome‐Like Overlap Following Venetoclax–Azacytidine and G‐CSF Therapy

JEADV Clinical Practice, EarlyView.
ABSTRACT Differentiation syndrome (DS) and Sweet syndrome (SS) are inflammatory complications mediated by cytokine dysregulation, classically associated with therapies that promote myeloid differentiation or cytokine release. While DS has been primarily linked to all‐trans retinoic acid (ATRA) and IDH inhibitors, recent evidence suggests that ...
Katerina Grafanaki, Maria Gerbesi, Zoe Apalla, Dimitrios Tsokanas, Efstathia Pasmatzi, Alexandros Spyridonidis, Maria Liga   +6 more
wiley   +1 more source

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia [PDF]

, 2017
Drug sensitivity and resistance testing on diagnostic leukemia samples should provide important functional information to guide actionable target and biomarker discovery.
Balasubramanian, Gnana P., Bandapalli, Obul R., Bornhauser, Beat C., Bourquin, Jean-Pierre, Brown, Timothy J., Cario, Gunnar, Chang, Bill H., Collins, Robert H., Delorenzi, Mauro, Diaz-Flores, Ernesto, Dobay, Maria Pamela, Dunn, Samuel H., Eckert, Cornelia, Eugster, Sabrina, Frismantas, Viktoras, Higi, Salome, Horvath, Peter, Irving, Julie A., Jenni, Silvia, Kulozik, Andreas E., Kunz, Joachim, Loh, Mignon L., Marovca, Blerim, Meisel, Roland, Muckenthaler, Martina U., Pail, Orrin, Radimerski, Thomas, Richter-Pechanska, Paulina, Rinaldi, Anna, Saha, Vaskar, Schrappe, Martin, Stanulla, Martin, Tchinda, Joelle, Tyner, Jeffrey W., Uhrig, Sebastian, Voegeli, Pamela, Von Stackelberg, Arend   +36 more
core   +1 more source

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors [PDF]

, 2020
Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8+ cytotoxic T lymphocyte (CTL ...
Chen, Liang, Chen, Zhipeng, Coleman, James, Ding, Ke, Dong, Changjiang, Fan, Zhenzhen, Gao, Song, He, Jingjing, Huang, Junqi, Li, Nan, Liu, Lu, Tian, Yahui, Xu, Chenqi, Zhang, Zhimin, Zhou, Penghui, Zhou, Qian   +15 more
core   +1 more source

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial [PDF]

, 2019
Aprospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (RHDS) versus conventional chemotherapy with rituximab (CHOP-R) as firstline therapy in 134 high-risk follicular ...
Angrilli, F., Barbui, A. M., Benedetti, F., Billio, A., Boccomini, C., Bruna, R., Castellino, C., Ciceri, F., Corradini, P., Devizzi, L., Di Raimondo, F., Dondi, A., Gini, G., Gueli, A., Ladetto, M., Lanza, F., Liberati, A. M., Mantoan, B., Massimo Gianni, A., Musso, M., Narni, F., Parvis, G., Passera, R., Patti, C., Perrone, T., Pulsoni, A., Rambaldi, A., Rossini, F., Rota-Scalabrini, D., Semenzato, G., Stelitano, C., Tarella, C., Tucci, A., Zallio, F., Zoli, V.   +34 more
core   +4 more sources

CRISPR‐Cas9 Genome‐Wide Screening in Paediatric Cancer: Functional Genomics for Target Discovery and the Improvement of Existing Therapies

Medicinal Research Reviews, EarlyView.
ABSTRACT CRISPR‐Cas9 genome‐wide screening has been instrumental towards identifying novel targets for drug discovery in cancer research. However, much of this research has centred specifically on adult cancers, with paediatric cancers being underserviced by current research and screening.
Steven He, Patrick Connerty, Antoine de Weck   +2 more
wiley   +1 more source

Interindividual variability in CYP3A‐mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia

Clinical and Translational Science
Venetoclax is a first‐in‐class orally administered B‐cell lymphoma‐2 inhibitor used to treat chronic lymphocytic leukemia (CLL). Venetoclax is primarily metabolized in the liver by cytochrome P450 (CYP) 3A4 to its major metabolite M27, via M5, and M2, M3,
Jonghwa Lee, Jessica L. Beers, Isabel Cheng, Vivian Truong, Zachary Brown, Benyam Muluneh, Catherine C. Coombs, Klarissa D. Jackson   +7 more
doaj   +1 more source

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. [PDF]

, 2016
Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that
Chen, L, Chen, Y, Choi, MY, Cui, B, Kipps, TJ, Rassenti, LZ, Widhopf Ii, GF, Wu, Christina, Yu, J, Zhang, L   +9 more
core   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Targeting METTL3 mitigates venetoclax resistance via proteasome-mediated modulation of MCL1 in acute myeloid leukemia

Cell Death and Disease
Venetoclax, a selective BCL2 inhibitor, is extensively utilized in clinical settings for the treatment of acute myeloid leukemia (AML). However, its efficacy is often compromised by the development of drug resistance.
Chang-qing Jiao, Chen Hu, Meng-hua Sun, Yan Li, Chao Wu, Fei Xu, Lei Zhang, Fu-rong Huang, Jun-jie Zhou, Ji-fei Dai, Min Ruan, Wen-chao Wang, Qing-song Liu, Jian Ge   +13 more
doaj   +1 more source

Dose‐dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy

British Journal of Haematology, EarlyView.
Prospective functional MRI brain and neurocognitive assessments were performed serially during intensive chemotherapy for a cohort of adults with newly diagnosed acute myeloid leukaemia to elucidate ‘chemobrain’ language phenomena. At completion of consolidation, significant reductions in functional and microstructural connectivity were observed ...
Ashleigh P. Scott, Ada Lo, Ying Xia, Kate Thompson, Harriet Bodimeade, Amir Fazlollahi, Nicholas Weber, Cameron Curley, Stewart Hunt, Kirk Morris, Caroline McNamara, Nilu Perera, Elango Subramoniapillai, Steven W. Lane, Glen A. Kennedy, Olivier Salvado, Javier Urriola, Katie L. McMahon   +17 more
wiley   +1 more source